Strides Pharma Science is currently trading at Rs. 842.10, up by 4.20 points or 0.50% from its previous closing of Rs. 837.90 on the BSE.

The scrip opened at Rs. 847.85 and has touched a high and low of Rs. 850.75 and Rs. 839.75 respectively. So far 3229 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 860.00 on 09-Apr-2024 and a 52 week low of Rs. 304.85 on 11-Apr-2023.

Last one week high and low of the scrip stood at Rs. 860.00 and Rs. 823.50 respectively. The current market cap of the company is Rs. 7741.17 crore.

The promoters holding in the company stood at 27.39%, while Institutions and Non-Institutions held 38.86% and 33.75% respectively.

Strides Pharma Science’s step‐down wholly owned subsidiary -- Strides Pharma Global, Singapore, has received approval for Fluoxetine Tabs 10 mg and 20 mg, from the United States Food & Drug Administration (USFDA).   

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly.  Fluoxetine tablets has a market size of $ 23.9 million as per IMS. This approval further strengthens the company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a market size of $106 million. The Fluoxetine tablets will be manufactured at the company’s facility in Puducherry.

The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 245 ANDAs have been approved. The company has set a target to launch 60 new products over three years in the US.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.